BIOCRYST director receives stock grant as board retainer
Frank Steven reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Frank Steven reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Steven Frank received a stock award instead of cash compensation. He was granted 1,262 shares of common stock at a reference value of $8.91 per share on May 29, 2026, issued in lieu of a $11,250 quarterly board cash retainer. After this grant, he directly holds 20,165 shares of BIOCRYST common stock. This is a routine, compensation-related equity award rather than an open-market purchase.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 1,262 | $8.91 | $11K |
Footnotes (1)
- F1. Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250.
Key Figures
Key Terms
Form 4 regulatory
Common Stock financial
Grant, award, or other acquisition financial
Board Member retainer financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BIOCRYST (BCRX) director Steven Frank report in this Form 4?
Was Steven Frank’s BIOCRYST (BCRX) Form 4 transaction an open-market stock purchase?
What does the $8.91 figure in the BIOCRYST (BCRX) Form 4 represent?
AI-generated analysis. How Rhea-AI works. Not financial advice.